1573 related articles for article (PubMed ID: 20217518)
21. Hematopoietic stem cell therapy for type 1 diabetes: induction of tolerance and islet cell neogenesis.
Burt RK; Oyama Y; Traynor A; Kenyon NS
Autoimmun Rev; 2002 May; 1(3):133-8. PubMed ID: 12849006
[TBL] [Abstract][Full Text] [Related]
22. Analysis of antigen specific T cells in diabetes - Lessons from pre-clinical studies and early clinical trials.
Krishnamurthy B; Selck C; Chee J; Jhala G; Kay TW
J Autoimmun; 2016 Jul; 71():35-43. PubMed ID: 27083395
[TBL] [Abstract][Full Text] [Related]
23. Thymic self-antigens for the design of a negative/tolerogenic self-vaccination against type 1 diabetes.
Geenen V; Mottet M; Dardenne O; Kermani H; Martens H; Francois JM; Galleni M; Hober D; Rahmouni S; Moutschen M
Curr Opin Pharmacol; 2010 Aug; 10(4):461-72. PubMed ID: 20434402
[TBL] [Abstract][Full Text] [Related]
24. Disease-modifying immunotherapy for the management of autoimmune diabetes.
Castro CN; Barcala Tabarrozi AE; Noguerol MA; Liberman AC; Dewey RA; Arzt E; Morelli AE; Perone MJ
Neuroimmunomodulation; 2010; 17(3):173-6. PubMed ID: 20134195
[TBL] [Abstract][Full Text] [Related]
25. Experimental autoimmune insulitis. Induction by T lymphocytes specific for a peptide of proinsulin.
Griffin AC; Zhao W; Wegmann KW; Hickley WF
Am J Pathol; 1995 Sep; 147(3):845-57. PubMed ID: 7545875
[TBL] [Abstract][Full Text] [Related]
26. Changing faces, unmasking the beta-cell: post-translational modification of antigens in type 1 diabetes.
van Lummel M; Zaldumbide A; Roep BO
Curr Opin Endocrinol Diabetes Obes; 2013 Aug; 20(4):299-306. PubMed ID: 23770733
[TBL] [Abstract][Full Text] [Related]
27. Adjuvant immunotherapy increases beta cell regenerative factor Reg2 in the pancreas of diabetic mice.
Huszarik K; Wright B; Keller C; Nikoopour E; Krougly O; Lee-Chan E; Qin HY; Cameron MJ; Gurr WK; Hill DJ; Sherwin RS; Kelvin DJ; Singh B
J Immunol; 2010 Nov; 185(9):5120-9. PubMed ID: 20876350
[TBL] [Abstract][Full Text] [Related]
28. The potential role of dendritic cells in the therapy of Type 1 diabetes.
Lee CN; Lew AM; Wu L
Immunotherapy; 2013 Jun; 5(6):591-606. PubMed ID: 23725283
[TBL] [Abstract][Full Text] [Related]
29. Different islet protein expression profiles during spontaneous diabetes development vs. allograft rejection in BB-DP rats.
Christensen UB; Larsen PM; Fey S; Karlsen AE; Pociot F; Nerup J; Sparre T
Autoimmunity; 2006 Jun; 39(4):315-21. PubMed ID: 16891220
[TBL] [Abstract][Full Text] [Related]
30. Immunological reversal of autoimmune diabetes without hematopoietic replacement of beta cells.
Suri A; Calderon B; Esparza TJ; Frederick K; Bittner P; Unanue ER
Science; 2006 Mar; 311(5768):1778-80. PubMed ID: 16556846
[TBL] [Abstract][Full Text] [Related]
31. Immune markers of disease and therapeutic intervention in type 1 diabetes.
Roep BO
Novartis Found Symp; 2008; 292():159-71; discussion 171-3, 202-3. PubMed ID: 19203098
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy of type 1 diabetes--how to rationally prioritize combination therapies in T1D.
Boettler T; von Herrath M
Int Immunopharmacol; 2010 Dec; 10(12):1491-5. PubMed ID: 20667487
[TBL] [Abstract][Full Text] [Related]
33. Tolerogenic dendritic cells induce antigen-specific hyporesponsiveness in insulin- and glutamic acid decarboxylase 65-autoreactive T lymphocytes from type 1 diabetic patients.
Segovia-Gamboa N; Rodríguez-Arellano ME; Rangel-Cruz R; Sánchez-Díaz M; Ramírez-Reyes JC; Faradji R; González-Domínguez É; Sánchez-Torres C
Clin Immunol; 2014 Sep; 154(1):72-83. PubMed ID: 24993292
[TBL] [Abstract][Full Text] [Related]
34. Islet replacement vs. regeneration: hope or hype?
Ramiya V; Schatz D
Pediatr Diabetes; 2004; 5 Suppl 2():45-56. PubMed ID: 15601374
[TBL] [Abstract][Full Text] [Related]
35. Emerging Therapeutic Strategies to Restore Regulatory T Cell Control of Islet Autoimmunity in Type 1 Diabetes.
Volfson-Sedletsky V; Jones A; Hernandez-Escalante J; Dooms H
Front Immunol; 2021; 12():635767. PubMed ID: 33815387
[TBL] [Abstract][Full Text] [Related]
36. Does autoantigen administration inhibit recurrence of type 1 diabetes in transplanted islets?
Mojtahedi Z; Farjadian S; Ghaderi A
Med Hypotheses; 2005; 64(5):986-8. PubMed ID: 15780496
[TBL] [Abstract][Full Text] [Related]
37. Cell Therapy for Type 1 Diabetes: Current and Future Strategies.
Aghazadeh Y; Nostro MC
Curr Diab Rep; 2017 Jun; 17(6):37. PubMed ID: 28432571
[TBL] [Abstract][Full Text] [Related]
38. Novel therapies in the management of type I diabetes mellitus.
Ludvigsson J
Panminerva Med; 2012 Dec; 54(4):257-70. PubMed ID: 23123577
[TBL] [Abstract][Full Text] [Related]
39. Peptide immunotherapies in Type 1 diabetes: lessons from animal models.
Fierabracci A
Curr Med Chem; 2011; 18(4):577-86. PubMed ID: 21143110
[TBL] [Abstract][Full Text] [Related]
40. Mechanistic basis of immunotherapies for type 1 diabetes mellitus.
Chen W; Xie A; Chan L
Transl Res; 2013 Apr; 161(4):217-29. PubMed ID: 23348026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
